Avidity Partners Management LP recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
2828 N HARWOOD STREET DALLAS, TX 75201
As of the latest 13F report, the guru’s equity portfolio contained 91 stocks valued at a total of $4,506,000,000. The top holdings were AZN(5.45%), ABBV(5.27%), and ARVN(4.35%).
According to GuruFocus data, these were Avidity Partners Management LP’s top five trades of the quarter.
Merck & Co Inc
The guru established a new position worth 2,370,000 shares in NYSE:MRK, giving the stock a 4.32% weight in the equity portfolio. Shares traded for an average price of $78.84 during the quarter.
On 05/16/2022, Merck & Co Inc traded for a price of $92.455 per share and a market cap of $232,763,859,000. The stock has returned 24.07% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Merck & Co Inc has a price-earnings ratio of 16.47, a price-book ratio of 5.70, a price-earnings-to-growth (PEG) ratio of 2.21, a EV-to-Ebitda ratio of 12.76 and a price-sales ratio of 4.32.
The price-to-GF Value ratio is 0.91, earning the stock a GF Value rank of 9.
Pfizer Inc
The guru sold out of their 2,090,000-share investment in NYSE:PFE. Previously, the stock had a 2.62% weight in the equity portfolio. Shares traded for an average price of $51.88 during the quarter.
On 05/16/2022, Pfizer Inc traded for a price of $50.7862 per share and a market cap of $283,322,184,000. The stock has returned 28.43% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Pfizer Inc has a price-earnings ratio of 11.58, a price-book ratio of 3.67, a price-earnings-to-growth (PEG) ratio of 1.11, a EV-to-Ebitda ratio of 8.56 and a price-sales ratio of 3.12.
The price-to-GF Value ratio is 0.63, earning the stock a GF Value rank of 4.
Arena Pharmaceuticals Inc
The guru sold out of their 1,215,500-share investment in NAS:ARNA. Previously, the stock had a 2.4% weight in the equity portfolio. Shares traded for an average price of $93.48 during the quarter.
On 05/16/2022, Arena Pharmaceuticals Inc traded for a price of $99.99 per share and a market cap of $6,165,322,000. The stock has returned 29.74% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, Arena Pharmaceuticals Inc has a price-book ratio of 9.14, a EV-to-Ebitda ratio of -9.08 and a price-sales ratio of 99990.00.
Intuitive Surgical Inc
The guru established a new position worth 325,000 shares in NAS:ISRG, giving the stock a 2.18% weight in the equity portfolio. Shares traded for an average price of $292.21 during the quarter.
On 05/16/2022, Intuitive Surgical Inc traded for a price of $220.8668 per share and a market cap of $78,462,510,000. The stock has returned -18.22% over the past year.
GuruFocus gives the company a financial strength rating of 10 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Intuitive Surgical Inc has a price-earnings ratio of 48.60, a price-book ratio of 6.48, a price-earnings-to-growth (PEG) ratio of 4.15, a EV-to-Ebitda ratio of 34.87 and a price-sales ratio of 13.55.
The price-to-GF Value ratio is 0.72, earning the stock a GF Value rank of 10.
Eli Lilly and Co
The guru sold out of their 344,800-share investment in NYSE:LLY. Previously, the stock had a 2.02% weight in the equity portfolio. Shares traded for an average price of $256.89 during the quarter.
On 05/16/2022, Eli Lilly and Co traded for a price of $302.6 per share and a market cap of $286,444,602,000. The stock has returned 51.48% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Eli Lilly and Co has a price-earnings ratio of 45.28, a price-book ratio of 30.71, a price-earnings-to-growth (PEG) ratio of 2.35, a EV-to-Ebitda ratio of 34.51 and a price-sales ratio of 9.37.
The price-to-GF Value ratio is 1.44, earning the stock a GF Value rank of 3.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
